降脂宁肝胶囊(Jiangzhi Ninggan Capsule)

概要

基本信息

药物类型

中药

别名-

靶点-

作用机制-

治疗领域

消化系统疾病

在研适应症-

非在研适应症

非酒精性脂肪性肝炎

原研机构-

在研机构-

非在研机构

广州市博岛医药高新技术研究中心

广州白云山汉方现代药业有限公司

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)无进展

特殊审评-

登录后查看时间轴

关联

2

项与降脂宁肝胶囊相关的临床试验

CTR20131783 / Completed临床2期

降脂宁肝胶囊治疗非酒精性脂肪性肝病-痰瘀互结证的随机、双盲单模拟、安慰剂平行对照多中心Ⅱ期临床试验

初步评价降脂宁肝胶囊治疗非酒精性单纯性脂肪肝-痰瘀互结证的有效性和安全性，探索安全有效剂量，为Ⅲ期临床试验提供用药依据。

开始日期2009-07-23

申办/合作机构

广州白云山汉方现代药业有限公司

[+1]

CTR20131780 / Completed临床2期

降脂宁肝胶囊治疗非酒精性脂肪性肝炎-痰瘀互结证随机双盲单模拟安慰剂平行对照多中心II期临床试验

初步评价降脂宁肝胶囊治疗非酒精性脂肪性肝炎-痰瘀互结证的有效性和安全性，探索安全有效剂量，为Ⅲ期临床试验提供用药依据。

开始日期2009-07-23

申办/合作机构

广州白云山汉方现代药业有限公司

[+1]

100 项与降脂宁肝胶囊相关的临床结果

登录后查看更多信息

100 项与降脂宁肝胶囊相关的转化医学

登录后查看更多信息

100 项与降脂宁肝胶囊相关的专利（医药）

登录后查看更多信息

2

项与降脂宁肝胶囊相关的文献（医药）

2022-05-01·Chemistry & Biodiversity3区 · 化学

Effect of Jiangan‐Jiangzhi Pill on Gut Microbiota and Chronic Inflammatory Response in Rats with Non‐Alcoholic Fatty Liver

3区 · 化学

Article

作者: Lei, Jinyan ; Ren, Wei ; Jia, Jianwei ; Wang, Li ; Zhao, Zeyu ; Bian, Yuhong ; Wang, Jing ; Miao, Jing ; Guo, Liying ; Wang, Yixi

AbstractNon‐alcoholic fatty liver disease (NAFLD) is a chronic liver disease with high rates of occurrence. Research has found that NAFLD patients experience varying degrees of intestinal flora imbalance. There is evidence that traditional Chinese medicine (TCM) positively regulates imbalances in the gut microbiota caused by liver diseases. Jiangan‐Jiangzhi pill (JGJZ) is a common Chinese remedy that can treat NAFLD clinically. This article investigates how JGJZ affects NAFLD and assesses related changes in the intestinal flora. We established a NAFLD rat model by feeding them a high‐fat diet (HFD) and gave different interventions. After twelve weeks, the results revealed that JGJZ decreased the total cholesterol, triglyceride, alanine aminotransferase, and aspartate aminotransferase in the serum of NAFLD rats. Histopathological staining demonstrated that JGJZ relieved cellular fat accumulation in the liver. Inflammatory cytokine levels (IL‐6, IL‐1β, and TNF‐α) were down‐regulated. Analysis of 16S rRNA demonstrated that JGJZ changed the community compositional structure of gut microbiota, characterized by a decrease in the Firmicutes‐to‐Bacteroidetes ratio, and increased gut microbiota diversity and the abundance of dominant groups. Accordingly, our study illustrated that JGJZ exerted a better effect in treating HFD‐induced NAFLD, which may be closely related to ameliorating gut microbiota dysbiosis.

Journal of Health, Population and Nutrition

Comparison of the efficacy and safety of Shanhuang Jiangzhi tablets and atorvastatin in the treatment of patients with hyperlipidaemia

Article

作者: Liang, XiuWen ; Sun, GuoTong

AbstractObjectivesTo compare the efficacy and safety of Shanhuang Jiangzhi tablets and atorvastatin in reducing blood lipid levels.MethodsPatients with hyperlipidaemia admitted to the cardiac centre between January 2019 and December 2020 were included in the study. A total of 1063 patients with hyperlipidaemia took either Shanhuang Jiangzhi tablets (n = 372) or atorvastatin (n = 691) and met the inclusion and exclusion criteria. Clinical data, including total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol, were retrospectively evaluated after propensity score matching (PSM) analysis. The adverse events were also recorded during the therapy process.ResultsFollowing PSM analysis, both groups were well matched across all parameters. Compared with the baseline, Shanhuang Jiangzhi tablets had greater effects on TC, TG and LDL-C, and the difference was statistically significant (p < 0.001). Furthermore, the results showed that Shanhuang Jiangzhi tablets are similar to atorvastatin in reducing TC and LDL-C, and all p-values were > 0.05. However, the decrease of TG was greater in the Shanhuang Jiangzhi group (p < 0.001). Clinical adverse reactions of Shanhuang Jiangzhi tablets are rare and have no statistical significance compared with atorvastatin (p = 0.682).ConclusionsShanhuang Jiangzhi tablets have a higher hypotriglyceridaemic performance than atorvastatin and an equivalent ability to lower TC and LDL-C. In addition, Shanhuang Jiangzhi tablets are a low-risk option for lowering blood lipids.

100 项与降脂宁肝胶囊相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非酒精性脂肪性肝炎	临床2期	中国	广州市博岛医药高新技术研究中心	2009-07-23
非酒精性脂肪性肝炎	临床2期	中国	广州白云山汉方现代药业有限公司	2009-07-23